Norges Bank’s CAMP4 Therapeutics CAMP Stock Holding History

Norges Bank’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-35,000	Closed	-$183K	–	1764
2024 Q4	$183K	Buy	+35,000	New	+$288K	﹤0.01%	1834

Other funds holding CAMP

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's CAMP Position: Q1 2025 in Review

Norges Bank sold out of CAMP4 Therapeutics (CAMP) in Q1 2025, closing a stake of 35,000 shares — an estimated $183K sold.

Norges Bank first reported a position in CAMP in Q4 2024 and held it in 1 quarter. The position peaked at $183K in Q4 2024. 39 funds tracked by Wall St. Rank hold CAMP as of Q1 2025.

Norges Bank reported no remaining CAMP4 Therapeutics position as of Q1 2025 after selling out during the quarter.
Norges Bank sold 35,000 CAMP4 Therapeutics shares in Q1 2025, an estimated $183K.
Norges Bank first reported a position in CAMP4 Therapeutics in Q4 2024 and held it in 1 quarter.
Norges Bank's CAMP4 Therapeutics position peaked at $183K in Q4 2024.
39 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.